- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00213486
Weekly Cisplatin/Irinotecan and Radiotherapy in Patients With Locally Advanced Esophageal Cancer: Phase II Trial
October 27, 2005 updated by: University Hospital, Rouen
The standard non surgical therapy of locally advanced esophageal cancer is based on a definitive concurrent chemoradiotherapy regimen with fluorouracil and cisplatin.
One of the alternative regimen which is being studied is the combination of a weekly cisplatin and irinotecan schedule with radiotherapy.
This multicentric phase II clinical trial primarily aimed to evaluate the clinical complete response rate and secondary objectives were toxicity profile and survival.
Study Overview
Detailed Description
Chemotherapy with weekly cisplatin 30 mg/m2 AND Irinotecan 60 mg/m2 was administered at days1,8,22,29 and concurrently with radiotherapy t days 43,50,64,71.
Radiotherapy was delivered day 43 to 75 with 50Gy in 25 fractions/5 weeks.
Study Type
Interventional
Enrollment
43
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Rouen, France, 76031
- CHU de Rouen
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- esophageal carcinoma (squamous cell or adenocarcinoma) histologically confirmed
- performance status <OR=2 (ECOG)
- caloric intake>1500 KCal/d
- serum albumin >32 gr/l
- serum creatinine<120 microgr/l
- total serum bilirubin < 1.5 mg/ml
- no prior chemotherapy or radiotherapy or surgery for esophageal neoplasm
- no prior history of malignancy other than cell carcinoma of the skin, in siyu cervical carcinoma, or head and neck carcinoma with complete response since 3 years
- written informed consent
Exclusion Criteria:
- Gilbert's syndrome
- cardiac disease as NYHA class 3 or 4
- myocardial infarction within the previous 6 months
- metastatic disease
- histologically proved invasion of tracheobronchial tree
- metastatic disease
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
clinical complete response defined as no tumor detectable on esophagus endoscopy and no appearance of distant metastasis on CT scan
|
Secondary Outcome Measures
Outcome Measure |
---|
toxicity profile
|
overall survival rate at one and two years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Pierre MICHEL, MD, Federation Francophone de Cancerologie Digestive
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2002
Study Completion
December 1, 2004
Study Registration Dates
First Submitted
September 13, 2005
First Submitted That Met QC Criteria
September 13, 2005
First Posted (Estimate)
September 21, 2005
Study Record Updates
Last Update Posted (Estimate)
October 28, 2005
Last Update Submitted That Met QC Criteria
October 27, 2005
Last Verified
September 1, 2005
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Head and Neck Neoplasms
- Esophageal Diseases
- Esophageal Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase Inhibitors
- Topoisomerase I Inhibitors
- Irinotecan
Other Study ID Numbers
- 2001/141/HP
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Esophageal Neoplasms
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage IIIA Esophageal Adenocarcinoma | Stage IIIB Esophageal Adenocarcinoma | Stage IIIC Esophageal Adenocarcinoma | Stage IIB Esophageal Adenocarcinoma | Stage IB Esophageal Adenocarcinoma | Stage IIA Esophageal AdenocarcinomaUnited States
-
University Hospital, LilleFederation of Research in Surgery (FRENCH); French Eso-Gastric Tumors Working... and other collaboratorsCompleted
-
University of Michigan Rogel Cancer CenterGenentech, Inc.TerminatedLoco-regional Esophageal Cancer
-
Universitaire Ziekenhuizen KU LeuvenCompletedEsophageal Carcinoma (Squamous Cell Carcinoma - Adenocarcinoma)Belgium
-
Emory UniversityNovartisCompletedEsophageal Cancer | Neoplasms, EsophagealUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityWithdrawnStage IIB Esophageal Cancer AJCC v7 | Stage III Esophageal Cancer AJCC v7 | Stage IIIA Esophageal Cancer AJCC v7 | Stage IIIB Esophageal Cancer AJCC v7 | Stage IIIC Esophageal Cancer AJCC v7
-
Tianjin Medical University Cancer Institute and...Sun Yat-sen University; Cancer Institute and Hospital, Chinese Academy of Medical... and other collaboratorsNot yet recruitingStage III Esophageal Cancer | Stage II Esophageal Cancer
-
Tianjin Medical University Cancer Institute and...UnknownStage III Esophageal Cancer | Stage II Esophageal CancerChina
-
Cancer Institute and Hospital, Chinese Academy...Peking University Cancer Hospital & InstituteRecruitingEsophageal Neoplasm Metastatic | Esophageal Cancer Stage IVbChina
-
Biotech Pharmaceutical Co., Ltd.Completed
Clinical Trials on irinotecan
-
Shanghai Zhangjiang Biotechnology Limited CompanyShanghai Biomabs Pharmaceutical Co., Ltd.CompletedMetastatic Colorectal Cancer
-
ShengFa SuUnknownSmall-cell Lung CancerChina
-
H. Lee Moffitt Cancer Center and Research InstituteTerminatedGlioma | Astrocytoma | OligodendrogliomaUnited States
-
Nelson YeeIpsenActive, not recruitingLocally Advanced Pancreatic Carcinoma(LAPC)United States
-
Centre Oscar LambretSFCECompleted
-
Boston Scientific CorporationBiocompatibles UK LtdCompletedMetastatic Colorectal CancerUnited Kingdom, Austria, France
-
Baohui HanNot yet recruitingExtensive-stage Small-cell Lung CancerChina
-
National Cancer Institute (NCI)CompletedExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditionsUnited States
-
Japan Clinical Cancer Research OrganizationTaiho Pharmaceutical Co., Ltd.Completed
-
Fudan UniversityNot yet recruitingSmall Cell Lung Cancer RecurrentChina